Interventional Pain Medicine · Nov 16, 2026

Weight loss in the management of spinal epidural lipomatosis: A narrative review with implications for interventional pain physicians

By Bokaee SA, Farid SD, Al Salak C et al.

Background Spinal epidural lipomatosis (SEL) is a pathological overgrowth of epidural adipose tissue that can result in spinal canal compromise, neurogenic claudication, and radiculopathy. Historically considered rare, SEL is increasingly recognized in patients with obesity, chronic corticosteroid exposure, or endocrine disorders. While surgical decompression has traditionally been the mainstay for severe neurological compromise, emerging evidence highlights weight reduction via lifestyle modification, pharmacotherapy, or bariatric surgery as a potentially beneficial and possibly disease-modifying approach in selected patients. Objectives To review the pathophysiology, risk factors, imaging characteristics, and management strategies for SEL, with emphasis on conservative and metabolic approaches relevant to interventional pain practice. Study design Narrative review. Setting Literature-based analysis of case reports, observational studies, and retrospective studies from international peer-reviewed journals. Methods A narrative review of peer-reviewed literature on SEL was conducted, focusing on patients with MRI-confirmed disease. Studies were evaluated to characterize physician-directed management strategies and factors associated with reduction of epidural fat. Both clinical outcomes (symptom improvement) and radiographic outcomes (changes in epidural fat volume) were assessed across case reports, observational studies, and imaging-based analyses. Results Weight reduction has been associated with radiographic reduction of epidural adipose tissue and symptom improvement in multiple case reports and observational studies. Case reports and cohort studies describe symptom improvement and imaging changes following BMI reduction in some patients, including those with prior surgical decompression or severe SEL. Emerging pharmacologic therapies, including GLP-1 receptor agonists, have been described in isolated case reports as a potential strategy to facilitate weight loss in obesity-associated SEL. Systemic corticosteroid exposure is commonly reported in association with SEL. Observational evidence has also described an association between epidural steroid injections and SEL progression, although the available data are limited and do not establish causality. Limitations Evidence is primarily derived from case reports, small observational cohorts, and retrospective analyses. Prospective, controlled studies assessing standardized outcomes are lacking. The heterogeneity of concomitant spinal pathology complicates direct attribution of symptom improvement to SEL-focused interventions. Conclusions SEL appears to be a metabolically associated and potentially reversible condition in some patients. Conservative management centered on weight reduction may be considered in selected patients with obesity-associated SEL, although current evidence is largely derived from case reports and observational studies. Recognition of SEL in pain practice may support a more integrated and mechanism-informed approach to care that addresses underlying metabolic drivers. The available literature supports further investigation of weight-loss strategies while emphasizing that current evidence is insufficient to establish weight loss as a definitive disease-modifying therapy. Findings were synthesized into a proposed, mechanism-informed treatment algorithm; this algorithm is not evidence-based and is intended to guide clinical reasoning and future investigation.

doi.org/10.1016/j.inpm.2026.100839Interventions

AgingResearch.News